Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R_xEACH study.

ABSTRACT:

Background

The R_xEACH randomized trial demonstrated that community pharmacist prescribing and care reduced the risk for cardiovascular (CV) events by 21% compared to usual care.

Objective

To evaluate the economic impact of pharmacist prescribing and care for CV risk reduction in a Canadian setting.

Methods

A Markov cost-effectiveness model was developed to extrapolate potential differences in long-term CV outcomes, using different risk assessment equations. The mean change in CV risk for the 2 groups of R_xEACH was extrapolated over 30 years, with costs and health outcomes discounted at 1.5% per year. The model incorporated health outcomes, costs and quality of life to estimate overall cost-effectiveness. It was assumed that the intervention would

SUBMITTER: Al Hamarneh YN 

PROVIDER: S-EPMC6610508 | biostudies-literature | 2019 Jul-Aug

REPOSITORIES: biostudies-literature